VANCOUVER, BC, March 31, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2022. “During the fourth quarter, Filament expanded its revenue-generating partnership network…


Previous articlePsychedelics Weekly – Investors Form REIT for Psychedelic Therapy, Diplo Runs a Marathon on LSD, and Is Cannabis a Psychedelic?
Next articleMindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023